Picard Medical CEO to present Emperor TAH data at CSI Focus D-HF in Frankfurt

Picard Medical, Inc.

CEO Patrick NJ Schnegelsberg presenting on December 6, 2025 at 13:00 CET in the 'Durable Mechanical Circulatory Support' session.
Emperor Total Artificial Heart (TAH) is a fully implantable device; Picard's subsidiary SynCardia makes the first FDA/Health Canada-approved total artificial heart.
Conference runs December 5-6, 2025 in Frankfurt, Germany; no new financial or operational guidance disclosed in the release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.